Dr.ย Byoung Chulย Cho
MD, PhD
Professor, Medical Oncology
corporate_fareYonsei Cancer Center / Severance Hospital, Seoul
Byoung Chul Cho
MD, PhD
Prof. Byoung Chul Cho is a Professor of Medical Oncology and a leading thoracic oncology specialist at Yonsei Cancer Center / Severance Hospital in Seoul, South Korea. He is internationally recognised for his work in EGFR-mutated non-small cell lung cancer (NSCLC), with particular focus on EGFR exon 20 insertion mutations and the development of bispecific antibody-based treatment strategies.
With over 20 years of clinical and research experience, Prof. Cho has been a principal investigator in several landmark global lung cancer trials, including pivotal studies evaluating amivantamab and lazertinib in EGFR-driven NSCLC. His clinical approach integrates comprehensive molecular profiling, biomarker-directed therapy, and access to international clinical trials for patients with advanced or treatment-resistant lung cancer. He manages a wide spectrum of thoracic malignancies, including EGFR-mutated NSCLC, EGFR exon 20 insertion NSCLC, and thymic tumours. Prof. Cho is widely cited in the global thoracic oncology community and his research has helped shape treatment guidelines for molecularly defined lung cancer subtypes.
CancerFax can coordinate medical report review and consultation support for international patients seeking an expert opinion from Prof. Byoung Chul Cho at Yonsei Cancer Center / Severance Hospital.
Why Consider Prof. Byoung Chul Cho?
Prof. Cho is one of the most recognised lung cancer specialists globally, with particular expertise in molecularly driven NSCLC and access to cutting-edge treatments and clinical trials at one of South Korea's leading cancer hospitals.
Areas of Specialisation
Precision lung cancer care guided by molecular profiling and clinical evidence
Prof. Byoung Chul Cho specialises in thoracic oncology with a focus on EGFR-mutated non-small cell lung cancer, EGFR exon 20 insertion NSCLC, and novel targeted treatment strategies including bispecific antibody combinations.
EGFR-Mutated NSCLC
Targeted treatment strategies for patients with EGFR-driven non-small cell lung cancer, including first-line, later-line, and resistance settings.
- arrow_rightAmivantamab-based treatment for EGFR exon20 insertion mutations
- arrow_rightMolecular characterisation and treatment planning for this difficult-to-treat subtype
- arrow_rightManagement of patients with limited response to older EGFR inhibitors
- arrow_rightLazertinib and amivantamab combination strategies
- arrow_rightTreatment planning after resistance to EGFR tyrosine kinase inhibitors
- arrow_rightBiomarker-guided selection of targeted versus immunotherapy approaches
Targeted Therapy & Immunotherapy
Systematic personalised treatment selection based on comprehensive molecular testing for lung cancer and related thoracic malignancies.
- arrow_rightEGFR, ALK, ROS1, MET, RET, NTRK, HER2, BRAF, KRAS-directed therapy
- arrow_rightMolecular profiling including NGS and ctDNA to guide treatment selection
- arrow_rightCombination antibody-based therapies including EGFR-MET bispecific agents
- arrow_rightPD-1 and PD-L1 checkpoint inhibitor selection based on TMB and PD-L1 expression
- arrow_rightChemoimmunotherapy combinations for suitable patients
- arrow_rightEvaluation of immunotherapy sequencing after targeted therapy
Thoracic Oncology โ Broader Scope
Management of thymic tumours and other rare or complex thoracic malignancies alongside advanced lung cancer.
- arrow_rightMultidisciplinary evaluation and systemic treatment planning for thymic carcinoma and thymoma
- arrow_rightClinical trial access for rare thoracic malignancies where standard options are limited
Procedures & Treatment Approaches
Evidence-based systemic and targeted treatment for advanced lung cancer
Prof. Cho's clinical practice covers the full range of systemic treatment options for thoracic malignancies, with a strong emphasis on molecularly guided therapy, clinical trials, and management of treatment-resistant disease.
Targeted Therapy for EGFR-Mutated NSCLC
Targeted TherapyPrecision targeting of EGFR-driven lung cancers using approved and investigational agents, including combination strategies for exon 20 insertions and resistance settings.
Medical Oncology for Lung Cancer
Medical OncologyComprehensive systemic treatment planning for advanced and metastatic non-small cell and small cell lung cancer.
Clinical Trial Access
Complex DiseaseEvaluation of eligibility for international lung cancer clinical trials, particularly in EGFR-driven and molecularly defined NSCLC.
Molecular Diagnosis & Treatment Planning
DiagnosisComprehensive biomarker evaluation to guide precise treatment decisions for lung cancer patients.
Second Opinion โ Lung Cancer
Second OpinionInternational second opinions for patients with advanced or complex lung cancer seeking expert review of their diagnosis and treatment plan.
Research & Publications
Internationally cited contributions to EGFR-mutated lung cancer and precision thoracic oncology
Prof. Byoung Chul Cho is among the most recognised clinical researchers in thoracic oncology globally, with key contributions to EGFR exon 20 insertion NSCLC research, amivantamab development, lazertinib clinical trials, and precision oncology in lung cancer.
Prof. Cho's complete list of peer-reviewed publications is available via PubMed and Google Scholar. Patients and referring physicians may contact CancerFax for a case-specific research summary.
Education & Training
Prof. Cho completed his medical training at Yonsei University, one of South Korea's most prestigious academic medical institutions, and pursued advanced research training in the United States.
Clinical Experience
Prof. Byoung Chul Cho has spent his career at Yonsei Cancer Center / Severance Hospital, building one of South Korea's most internationally recognised thoracic oncology programmes over more than 20 years of clinical and research practice.
Languages & International
Prof. Cho consults in the following languages.
CancerFax can coordinate professional medical interpreter support for international patients requiring assistance in languages other than English or Korean.
CancerFax can coordinate professional medical interpreter support for patients consulting in other languages.
How CancerFax Helps You Access Dr. Byoung Chul Cho
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Byoung Chul Cho's team โ with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history โ prepared as a structured clinical summary for Dr. Byoung Chul Cho's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Byoung Chul Cho before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Byoung Chul Cho's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Byoung Chul Cho's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Byoung Chul Cho's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Prof. Byoung Chul Cho
Prof. Byoung Chul Cho is a Professor of Medical Oncology and thoracic oncology specialist at Yonsei Cancer Center / Severance Hospital in Seoul, South Korea. He is internationally recognised for his work in EGFR-mutated non-small cell lung cancer, EGFR exon 20 insertion NSCLC, and the clinical development of amivantamab and lazertinib.
Prof. Cho is best known for his contributions to EGFR exon 20 insertion lung cancer research and his role in landmark clinical trials involving amivantamab (an EGFR-MET bispecific antibody) and lazertinib. His work has helped establish new treatment standards for patients with EGFR-driven NSCLC, including those who have progressed after earlier EGFR inhibitors.
Yes. EGFR exon 20 insertion NSCLC is one of Prof. Cho's primary areas of expertise. He has been closely involved in clinical trials evaluating amivantamab and other agents designed specifically for this molecularly distinct subtype, which historically had limited response to older EGFR tyrosine kinase inhibitors.
Prof. Cho is based at Yonsei Cancer Center / Severance Hospital, part of the Yonsei University Health System in Seoul, South Korea. Severance Hospital is one of South Korea's leading academic medical centres and has a structured international patient programme.
Yes. International patients with lung cancer, EGFR-mutated NSCLC, or EGFR exon 20 insertion mutations may seek consultation at Yonsei Cancer Center / Severance Hospital. CancerFax can help coordinate medical report review, case preparation, and appointment planning, subject to hospital availability and case acceptance.
Submit your medical reports through CancerFax. The CancerFax team will review your documents, prepare a structured case summary, and coordinate the next steps with Yonsei Cancer Center / Severance Hospital. Relevant documents include pathology reports, molecular or NGS test results, PET-CT and imaging reports, and previous treatment records.
Connect with Byoung Chul Cho Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.